title: Concept of an antiatherosclerotic efficacy of calcium entry blockers. INTACT Investigators.
abstract: Animal experiments suggest an inhibitory effect of calcium entry blockers on arterial calcinosis and the formation of atherosclerotic plaques. Experiments with isolated tissues suggest various mechanisms for an antiatherosclerotic effect of calcium entry blockers. INTACT, the International Nifedipine Trial on Antiatherosclerotic Therapy, is the first study investigating, with a prospective, placebo-controlled, randomized, double-blind design, the influence of a calcium entry blocker (nifedipine 80 mg/day) on the progression of coronary atherosclerosis in patients with proven coronary artery disease. Study endpoints were changes of established coronary stenoses (diameter reduction greater than or equal to 20%), as well as the formation of new stenoses as documented by coronary angiography. Standardized coronary angiograms were taken before and after a treatment period of 3 years. The angiograms were quantitatively analyzed with the computer-assisted edge detection system CAAS. Of the 425 patients included in the study, 282 patients (134 on nifedipine and 148 on placebo) revealed no protocol violations. In the inclusion angiograms of these patients, 893 coronary stenoses were detected which were not significantly influenced in their development by nifedipine. However, 196 entirely new coronary lesions, 185 stenoses and 11 occlusions, were found in the follow-up angiograms. There were 78 lesions in 54 patients (40%) on nifedipine (0.58 new lesions/patient) and 118 lesions in 73 patients (49%; n.s.) on placebo (0.8 new lesions/patient; p = 0.031). In two other studies on the inhibiting effect of dihydropyridine calcium entry blockers on the progression of coronary artery disease in man defining angiographic endpoints, the drugs were also shown to reduce the number of newly formed significant coronary lesions. If further trials in man confirm a protective role of calcium entry blockers against the formation of atherosclerotic coronary lesions, a new strategy in the prevention of coronary artery disease has to be considered.
authors.affiliation: Department of Cardiology, Hannover Medical School, FRG.
authors.forename: S
authors.initials: S
authors.lastname: Jost
authors.forename: W
authors.initials: W
authors.lastname: Rafflenbeul
authors.forename: J
authors.initials: J
authors.lastname: Deckers
authors.forename: B
authors.initials: B
authors.lastname: Wiese
authors.forename: H
authors.initials: H
authors.lastname: Hecker
authors.forename: P
authors.initials: P
authors.lastname: Nikutta
authors.forename: P
authors.initials: P
authors.lastname: Lippolt
authors.forename: P
authors.initials: P
authors.lastname: Lichtlen
mesh_terms: D000818:Animals; D001018:Aortic Diseases / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D001161:Arteriosclerosis / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D002114:Calcinosis / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000517:prevention & control; D004195:Disease Models, Animal; D004311:Double-Blind Method; D006801:Humans; D007391:International Cooperation; D008641:Mesenteric Vascular Occlusion / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D011817:Rabbits; D051381:Rats
chemical_list: D002121:Calcium Channel Blockers